Chronic urticaria: Difference between revisions

Line 18: Line 18:
**[[Diphenhydramine]]
**[[Diphenhydramine]]
**[[Famotidine]]
**[[Famotidine]]
*2nd line agents
*2nd line agents: TCAs
**[[Doxepin]] <ref> Simons FE, et al; Histamine and H1-antihistamines: celebrating a century of progress. PMID: 22035879 </ref>
**[[Doxepin]] <ref> Simons FE, et al; Histamine and H1-antihistamines: celebrating a century of progress. PMID: 22035879 </ref>
***Start at 10 mg daily and increase to 10 mg TID <ref> Yadav, S, et al; Management of difficult urticaria. PMID: 20161863 </ref>
***Start at 10 mg daily and increase to 10 mg TID <ref> Yadav, S, et al; Management of difficult urticaria. PMID: 20161863 </ref>
***Avoid if recent MI
***Avoid if liver dysfunction
**[[Mirtazapine]]
**[[Mirtazapine]]
***15 mg daily <ref> Bigatà X, et al; Severe chronic urticaria: response to mirtazapine. PMID: 16243165 </ref>
*Consider corticosteroids
*Consider corticosteroids
**[[methylprednisolone]] 125mg IV/IM OR [[prednisone]] 60mg PO
**[[methylprednisolone]] 125mg IV/IM OR [[prednisone]] 60mg PO

Revision as of 16:39, 1 August 2019

Background

  • Recurrent urticaria at least twice per week for 6 weeks [1]
  • Often autoimmune etiology

Clinical Features

  • Urticaria

Differential Diagnosis

Acute allergic reaction

Evaluation

Management

Disposition

  • Discharge if no concern for anaphylaxis

See Also

External Links

References

  1. Grattan, et al, Chronic urticaria; PMID: 22345759
  2. Simons FE, et al; Histamine and H1-antihistamines: celebrating a century of progress. PMID: 22035879
  3. Yadav, S, et al; Management of difficult urticaria. PMID: 20161863
  4. Bigatà X, et al; Severe chronic urticaria: response to mirtazapine. PMID: 16243165